Priavoid’s PRI-002 amyloid-detangling pill failed its Phase 2 study in Alzheimer’s disease, according to the company’s reported trial update. The German biotech had positioned PRI-002 as a small-molecule approach intended to disrupt small amyloid protein clumps implicated in disease progression. The setback adds to a growing list of Alzheimer programs confronting efficacy challenges after promising mechanistic rationale. For trial designers and sponsors, the result renews focus on patient selection, biomarker strategy, and what constitutes a meaningful signal early enough to justify Phase 3 investment. Investors will likely assess how Priavoid adjusts its development path—whether it revises dosing, targets a narrower population, or pivots to related compounds or combination strategies. In the near term, competitive pressure remains intense given continued payer scrutiny and the high cost of late-stage failures in neurodegeneration. The update also reinforces the importance of translational alignment between amyloid engagement measures and cognitive outcomes, given that the field continues to debate which endpoints best predict clinically relevant benefit.